EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 572 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pelitinib
CAS:Fórmula:C24H23ClFN5O2Pureza:>97.0%(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:467.93Tyrphostin A1
CAS:Fórmula:C11H8N2OPureza:>98.0%(GC)Forma y color:Light orange to Yellow to Green powder to crystalPeso molecular:184.20Lapatinib
CAS:Fórmula:C29H26ClFN4O4SPureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:581.06Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:294.31Tyrphostin A23
CAS:Fórmula:C10H6N2O2Pureza:>98.0%(GC)Forma y color:White to Light yellow powder to crystalPeso molecular:186.17Tyrphostin AG 835
CAS:Fórmula:C18H16N2O3Pureza:>98.0%(HPLC)Forma y color:Light yellow to Amber to Dark green powder to crystalPeso molecular:308.34Curcumin (Synthetic)
CAS:Fórmula:C21H20O6Pureza:>97.0%(T)Forma y color:Light yellow to Brown powder to crystalPeso molecular:368.39Butein
CAS:Fórmula:C15H12O5Pureza:>98.0%(HPLC)Forma y color:Light yellow to Brown powder to crystalPeso molecular:272.26Genistein
CAS:Fórmula:C15H10O5Pureza:>98.0%(HPLC)Forma y color:White to Light yellow to Light orange powder to crystalPeso molecular:270.24Gefitinib
CAS:Fórmula:C22H24ClFN4O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:446.91Tyrphostin AG 494
CAS:Fórmula:C16H12N2O3Pureza:>98.0%(HPLC)(N)Forma y color:Light yellow to Amber to Dark green powder to crystalPeso molecular:280.28Methyl 2,5-Dihydroxycinnamate
CAS:Fórmula:C10H10O4Pureza:>96.0%(HPLC)Forma y color:White to Yellow powder to crystalPeso molecular:194.19Erlotinib Hydrochloride
CAS:Fórmula:C22H23N3O4·HClPureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:429.90Curcumin (Natural)
CAS:Fórmula:C21H20O6Forma y color:Light yellow to Brown powder to crystalPeso molecular:368.39PD 153035 Hydrochloride
CAS:Fórmula:C16H14BrN3O2·HClPureza:>97.0%(HPLC)Forma y color:White to Light yellow to Light orange powder to crystalPeso molecular:396.67Tyrphostin AG528
CAS:Fórmula:C18H14N2O3Pureza:>97.0%(HPLC)Forma y color:Light yellow to Amber to Dark green powder to crystalPeso molecular:306.32Khellin
CAS:<p>Khellin (Methafrone) is a vasodilator that also has bronchodilatory action.</p>Fórmula:C14H12O5Pureza:99.89% - 99.95%Forma y color:Light Yellow CrystallinePeso molecular:260.24Losatuxizumab
CAS:<p>Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody with potential anti-tumor activity for the study of advanced malignant solid tumors.</p>Pureza:97.3% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.3% (SDS-PAGE); 95.1% (SEC-HPLC)Forma y color:LiquidAZ7550 hydrochloride
CAS:<p>AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Fórmula:C27H32ClN7O2Pureza:99.65%Forma y color:SolidPeso molecular:522.04Erlotinib
CAS:<p>Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.</p>Fórmula:C22H23N3O4Pureza:98.19% - 99.98%Forma y color:White To Off-White PowderPeso molecular:393.44LCH-7749944
CAS:<p>LCH-7749944 suppresses human gastric cancer cell growth, induces apoptosis, and inhibits PAK4 with IC50 of 14.93 μM.</p>Fórmula:C20H22N4O2Pureza:99.48%Forma y color:SolidPeso molecular:350.41Propanedinitrile,2-[(4-methoxyphenyl)methylene]-
CAS:Fórmula:C11H8N2OPureza:98%Forma y color:SolidPeso molecular:184.1940Mutated EGFR-IN-1
CAS:<p>Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating</p>Fórmula:C25H31N7OPureza:98.91%Forma y color:SolidPeso molecular:445.56(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Fórmula:C17H14N2O3Pureza:98%Forma y color:SolidPeso molecular:294.30471-[4-[4-[[2-[(1E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole
CAS:Fórmula:C25H23F3N4O2Pureza:98%Forma y color:SolidPeso molecular:468.4709Gefitinib
CAS:<p>Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations.</p>Fórmula:C22H24ClFN4O3Pureza:99.92% - >99.99%Forma y color:Light-Yellow Crystalline PowderPeso molecular:446.9Pyrotinib dimaleate
CAS:<p>Pyrotinib dimaleate is a selective EGFR/HER2 dual inhibitor, respectively, for the treatment of HER2-positive breast cancer.Cost-effective and quality-assured.</p>Fórmula:C40H39ClN6O11Pureza:97.27% - 99.52%Forma y color:SolidPeso molecular:815.22Barecetamab
CAS:<p>Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity.</p>Pureza:97.1% (SDS-PAGE); 96.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidGancotamab
CAS:<p>Gancotamab (MM-302) is a polyethylene glycolated liposome targeting HER2 with antitumor activity for the study of advanced HER2-positive breast cancer.</p>Pureza:96.7% (SDS-PAGE); 98.4% (SEC-HPLC) - 96.7% (SDS-PAGE); 98.4% (SEC-HPLC)Forma y color:LiquidIntetumumab
CAS:<p>Intetumumab (CNTO 95) is a fully humanized anti-α(v)-integrin monoclonal antibody that is a radiosensitizer for xenograft tumor-bearing mice.</p>Pureza:97.6% (SDS-PAGE); 97.1% (SEC-HPLC) - 97.6% (SDS-PAGE); 97.1% (SEC-HPLC)Forma y color:LiquidPeso molecular:145.6 (kDa)(2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
CAS:Fórmula:C30H29ClN6O3Pureza:98%Forma y color:SolidPeso molecular:557.0427O-Desmethyl gefitinib
CAS:<p>O-Desmethyl gefitinib is an active EGFR inhibitor (IC50: 36 nM), a metabolite of Gefitinib, formed by CYP2D6.</p>Fórmula:C21H22ClFN4O3Pureza:97.17%Forma y color:SolidPeso molecular:432.88Petosemtamab
CAS:<p>Petosemtamab (MCLA 158), a dual-action monoclonal antibody targets EGFR & LGR5, used in solid tumor research like HNSCC & CRC.</p>Pureza:> 95% - > 95%Forma y color:LiquidPeso molecular:145.97 kDaLapatinib ditosylate monohydrate
CAS:<p>Lapatinib ditosylate monohydrate: a drug for advanced breast cancer; may cause liver issues.</p>Fórmula:C29H26ClFN4O4S·2(C7H8O3S)·H2OPureza:98% - 99.41%Forma y color:Colourless To Light-Yellow CrystalPeso molecular:943.47N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
CAS:Fórmula:C29H26ClFN4O4SPureza:98%Forma y color:SolidPeso molecular:581.0575Ref: IN-DA0039KT
1g106,00€5g222,00€50g573,00€100gA consultar250gA consultar25mg29,00€100mg44,00€250mg56,00€4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-
CAS:Fórmula:C15H10O5Pureza:97%Forma y color:SolidPeso molecular:270.2369Ref: IN-DA00I8G3
1g26,00€5g24,00€10g31,00€1kg686,00€25g52,00€50g77,00€5kgA consultar100g114,00€10kgA consultar250g181,00€500g320,00€100mg26,00€Mevastatin
CAS:<p>Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum.</p>Fórmula:C23H34O5Pureza:99.12%Forma y color:White-Yellowish To Yellow Powder Solid PowderPeso molecular:390.512-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
CAS:Fórmula:C18H13BrN4OPureza:98%Forma y color:SolidPeso molecular:381.22604-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1)
CAS:Fórmula:C22H23ClN3O4Pureza:98%Forma y color:SolidPeso molecular:429.8967Epertinib hydrochloride
CAS:<p>Epertinib hydrochloride (S-22611 hydrochloride) shows potent antitumor activity.</p>Fórmula:C30H28Cl2FN5O3Pureza:99.14%Forma y color:SolidPeso molecular:596.48Erlotinib hydrochloride
CAS:<p>Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.</p>Fórmula:C22H23N3O4·HClPureza:99.78% - 99.85%Forma y color:White Or Off-White PowderPeso molecular:429.9Rociletinib
CAS:<p>Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic</p>Fórmula:C27H28F3N7O3Pureza:98.52% - 99.25%Forma y color:SolidPeso molecular:555.55Margetuximab
CAS:<p>Margetuximab (MGAH-22) is a second generation anti-HER2 monoclonal antibody with anti-tumor activity.</p>Pureza:95.3% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.3% (SDS-PAGE); 99.3% (SEC-HPLC)Forma y color:LiquidRilzabrutinib
CAS:<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Forma y color:SolidPeso molecular:665.76Methyl 2,5-Dihydroxycinnamate
CAS:Fórmula:C10H10O4Pureza:95%Forma y color:SolidPeso molecular:194.1840Lapatinib Ditosylate
CAS:<p>Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2).</p>Fórmula:C29H26ClFN4O4S·2C7H8O3SPureza:99.41%Forma y color:Yellow SolidPeso molecular:925.46N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
CAS:Fórmula:C22H24ClFN4O3Pureza:98%Forma y color:SolidPeso molecular:446.90244-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-
CAS:Fórmula:C16H14ClN3O2Pureza:99%Forma y color:SolidPeso molecular:315.7543Lapatinib
CAS:<p>Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity.</p>Fórmula:C29H26ClFN4O4SPureza:99.00% - 99.81%Forma y color:PowderPeso molecular:581.062H-1-Benzopyran-2-one, 7,8-dihydroxy-
CAS:Fórmula:C9H6O4Pureza:95%Forma y color:SolidPeso molecular:178.1415Allitinib
CAS:<p>Allitinib (AST-1306) (AST-1306) has anti-cancer activity，and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1]</p>Fórmula:C24H18ClFN4O2Pureza:99.89% - 99.91%Forma y color:SolidPeso molecular:448.88Panitumumab
CAS:<p>Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).</p>Pureza:95% - 98.1% (SDS-PAGE); 99.4% (SEC-HPLC)Forma y color:LiquidPeso molecular:147 kDaAV-412
CAS:<p>AV-412 (MP412) is an EGFR inhibitor (EGFR, EGFR T790M, EGFR L858R, EGFR L858R/T790M and ErbB2 with IC50s of 0.75, 0.79, 0.5, 2.3, 19 nM).</p>Fórmula:C41H44ClFN6O7S2Pureza:99.85% - 99.92%Forma y color:SolidPeso molecular:851.41(2E)-2-Cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)prop-2-enethioamide
CAS:Fórmula:C18H24N2OSPureza:95%Forma y color:SolidPeso molecular:316.4610(2E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-[(1S)-1-phenylethyl]-2-propenamide
CAS:Fórmula:C18H16N2O3Pureza:97%Forma y color:SolidPeso molecular:308.3312JBJ-07-149
CAS:<p>JBJ-07-149 is an inhibitor of EGFRL858R/T790M with an IC50 of 1.1 nM. It suppresses the proliferation of Ba/F3 cells with IC50 values of 4.9 μM when used alone, and 0.148 μM when combined with Cetuximab. Additionally, JBJ-07-149 can serve as a target protein ligand for synthesizing [DDC-01-163].</p>Fórmula:C28H26N6O2SForma y color:SolidPeso molecular:510.61FRF-06-057
<p>FRF-06-057 is an allosteric ATP EGFR inhibitor targeting both wild-type and mutant EGFR, with IC50 values of 17 nM (LR/TM), 29 nM (LR/TM/CS), 220 nM (LR), and >1000 nM (WT).</p>Fórmula:C19H13N3O3SForma y color:SolidPeso molecular:363.39Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Forma y color:Odour LiquidPD-149163 hydrochloride
<p>PD-149163 hydrochloride is a neurokinin B agonist with antipsychotic activity, used for research on neurological diseases.</p>Fórmula:C42H72ClN9O6Forma y color:SolidPeso molecular:834.53ARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Fórmula:C29H27N7O4SPureza:99.82%Forma y color:SolidPeso molecular:569.63Petosemtamab (FUT8-KO)
<p>Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).</p>Forma y color:Odour LiquidVislarafusp alfa
<p>Vislarafusp alfa is a humanized IgG1κ antibody that targets EGFR/CD47, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Forma y color:Odour LiquidBMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Fórmula:C27H29Cl2FN8O3Pureza:99.11%Forma y color:Odour SolidPeso molecular:603.47TX2-120-1
CAS:<p>TX2-120-1 possesses the ability to bind with Her3, exhibiting an IC50 of 56 nM for Her3. It can be utilized in the synthesis of TX2-121-1.</p>Fórmula:C26H27N7O2Forma y color:SolidPeso molecular:469.54Tyrosine kinase-IN-7
CAS:<p>Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity.</p>Fórmula:C16H15N3OSPureza:99.93%Forma y color:SolidPeso molecular:297.38Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PForma y color:SolidPeso molecular:805.72DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Forma y color:Odour SolidDepatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Forma y color:LiquidPeso molecular:148.24 kDaIBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Forma y color:Odour LiquidDP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Forma y color:LiquidBefotertinib
CAS:<p>Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.</p>Fórmula:C29H32F3N7O2Pureza:99.83%Forma y color:SolidPeso molecular:567.61WAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Forma y color:SolidPeso molecular:373.4EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SForma y color:SolidPeso molecular:916.06EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Forma y color:SolidPeso molecular:429.24163Calotatug
<p>Calotatug is a humanized IgG1κ antibody targeting ERBB2, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Forma y color:Odour LiquidJAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Fórmula:C16H19NOPureza:98%Forma y color:SolidPeso molecular:241.33EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Fórmula:C50H55ClFN5O5Forma y color:SolidPeso molecular:860.45CH7233163
<p>CH7233163 is a useful organic compound for research related to life sciences and the catalog number is T35334.</p>Pureza:98%Forma y color:SolidCaxmotabart
<p>Caxmotabart is a humanized IgG1κ antibody targeting ERBB2, with HumanIgG1kappa, Isotype Control as its corresponding isotype control.</p>Forma y color:Odour LiquidHDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OForma y color:SolidPeso molecular:355.76EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Forma y color:SolidPeso molecular:846.43Dalmitamig
<p>Dalmitamig is a humanized IgG4κ antibody targeting EGFR/CD28, with HumanIgG4(S228P) kappa as its corresponding isotype control.</p>Forma y color:Odour LiquidCinrebafusp alfa
CAS:<p>Cinrebafusp alfa (PRS 343) is an anticalin-based bispecific drug with high affinity for both CD137/HER2, displaying dissociation constants (Kd) of 0.3 nM to</p>Pureza:98%Forma y color:LiquidZenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Forma y color:LiquidHER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96PROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Fórmula:C60H77N13O5SForma y color:SolidPeso molecular:1092.4U3-1565
<p>U3-1565 (Anti-HB-EGF antibody) is an antibody targeting HB-EGF with potential anti-tumor activity, used in the study of advanced solid tumors.</p>Forma y color:LiquidPeso molecular:144.82 kDa (Predicted)Timigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Forma y color:LiquidTilatamig
<p>Tilatamig is a humanized antibody of the Ig(G1-κ, G1-λ2) type targeting EGFR/MET.</p>Forma y color:Odour LiquidMS9449
CAS:<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Fórmula:C60H76ClFN10O8SPureza:98%Forma y color:SolidPeso molecular:1151.82Self-assembling peptide pY1
<p>Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.</p>Fórmula:C104H125N24O29PForma y color:SolidPeso molecular:2206.22GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Forma y color:SoildPeso molecular:598.11AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Forma y color:SolidPeso molecular:480.854Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClForma y color:SolidPeso molecular:517.59HER2-IN-13
CAS:<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Fórmula:C31H37N7O2Pureza:99.62%Forma y color:SoildPeso molecular:539.67Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Forma y color:SolidPeso molecular:537.41YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Forma y color:Odour LiquidDSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidMS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Forma y color:SolidPeso molecular:1107.5EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Forma y color:SolidPeso molecular:524.633Azerutamig
<p>Azerutamig is a dual-specificity antibody targeting KLRK1/ERBB2 of type (H-γ1_L-κ)_scFvkh-H-γ1(h-CH2-CH3).</p>Forma y color:Odour LiquidMS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.47EGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Forma y color:Odour SolidAmivantamab (FUT8-KO)
<p>Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.</p>Fórmula:C13H12O4Forma y color:LiquidPeso molecular:232.23PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Fórmula:C49H65ClN10O7SForma y color:SolidPeso molecular:973.62PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Forma y color:Odour LiquidDSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Forma y color:Odour SolidSOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Forma y color:SolidPeso molecular:490.52Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Forma y color:LiquidEGFR ligand-11
CAS:<p>EGF Rligand-11, a target protein ligand for EGFR, is utilized in the synthesis of PROTAC MS154.</p>Fórmula:C25H29ClFN5O4Forma y color:SolidPeso molecular:517.98Nezutatug
CAS:<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Pureza:98%Forma y color:LiquidMC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Forma y color:SolidPeso molecular:1041.2Laprituximab
CAS:<p>Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.</p>Pureza:>95%Forma y color:LiquidEGFR-IN-138
<p>EGFR-IN-138 (compound 19) is a potent inhibitor of EGFR, with IC50 values of 37, 2.6, and 1.9 nM for the wild-type, L858R, and T790M EGFR, respectively.</p>Fórmula:C42H37N7O5Forma y color:SolidPeso molecular:719.79OK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Forma y color:SolidPeso molecular:907.03EGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSForma y color:SolidPeso molecular:490.984-Epidoxycycline
CAS:<p>4-Epidoxycycline is a hepatic metabolite of the antibiotic doxycycline and lacks antibiotic properties in mice. In both in vitro assays and in vivo mouse models, 4-Epidoxycycline regulates HER2 gene expression similarly to doxycycline and exhibits comparable efficacy in tumor tissues, achieving over 95% tumor regression rates.</p>Fórmula:C22H24N2O8Forma y color:SolidPeso molecular:444.44ErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Fórmula:C43H60N8O11Forma y color:SolidPeso molecular:864.98Etevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Forma y color:LiquidAMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Forma y color:Odour LiquidVarlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Fórmula:C27H20N4OForma y color:SolidPeso molecular:416.47EGFRvIII peptide (PEPvIII)
CAS:<p>PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.</p>Fórmula:C70H111N19O24SPureza:98%Forma y color:SolidPeso molecular:1634.81DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidCoprelotamab
CAS:<p>Coprelotamab (GB-221) is an IgG-κ monoclonal antibody that targets EGFR2, frequently produced in CHO DG44 (Chinese Hamster Ovary) cells [1].</p>Pureza:98%Forma y color:LiquidPROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Fórmula:C40H46ClN11O5Pureza:98%Forma y color:SolidPeso molecular:796.32EGFR-IN-84
<p>EGFR-IN-84 (Compound 6g), an EGFR inhibitor with an IC50 of 24 nM, impedes the growth of A549 cells with an IC50 value of 1.537 μM and is utilized for lung</p>Fórmula:C25H20N6O3S2Pureza:98%Forma y color:SolidPeso molecular:516.59EGFR-IN-81
<p>EGFR-IN-81 (Compound 10i), an EGFR inhibitor, demonstrates potent activity by inhibiting EGFR WT and the L858R/T790M mutation at IC50 values of 4.38 nM and 5.69</p>Fórmula:C28H24F3N5O4Pureza:98%Forma y color:SolidPeso molecular:551.52MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Fórmula:C20H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:392.82Dacomitinib metabolite M2
CAS:<p>Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.</p>Fórmula:C27H32ClFN6O4SForma y color:SolidPeso molecular:591.1Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Forma y color:Odour LiquidZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Fórmula:C13H10OPureza:98%Forma y color:SolidPeso molecular:182.222FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidEGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Fórmula:C26H27N7O3SForma y color:SolidPeso molecular:517.603EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Fórmula:C24H25BrN6O2Forma y color:SolidPeso molecular:509.408Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Forma y color:Odour SolidKRAS G12D inhibitor 25
CAS:<p>KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.</p>Fórmula:C56H62ClN11O6Forma y color:SolidPeso molecular:1020.62Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidFicerafusp alfa
<p>Ficerafusp alfa is a chimeric antibody of the IgG1κ type that targets EGFR, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Forma y color:Odour LiquidEGFR/BRAFV600E-IN-2
<p>E07 Aptamer, targeting the human epidermal growth factor receptor (hEGFR), competes with epidermal growth factor (EGF) for binding to a unique epitope on EGFR.</p>Fórmula:C25H18N4O2Pureza:98%Forma y color:SolidPeso molecular:406.44EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Fórmula:C17H16N4O4SForma y color:SolidPeso molecular:372.398EGFR-IN-79
<p>EGFR-IN-79 (compound 21), an EGFR inhibitor, exhibits antitumor activity through ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy.</p>Fórmula:C23H16ClN3O3Pureza:98%Forma y color:SolidPeso molecular:417.84EGFR-IN-90
<p>EGFR-IN-90 (compound 34), an orally active EGFR inhibitor, demonstrates potent activity against EGFRL858R/T790M/C797S with an IC50 of 5.1 nM and effectively</p>Pureza:98%Forma y color:Odour SolidBI-4732
CAS:<p>DL-Homocystine is a mutagen secreted by F. nucleatum.</p>Fórmula:C32H36N10O2Pureza:98.88%Forma y color:SolidPeso molecular:592.69CN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Fórmula:C12H12N4O6SForma y color:SolidPeso molecular:340.31EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C22H18FN3O3Peso molecular:391.13322Modotuximab
CAS:<p>Modotuximab (DS 1024) is a humanized antibody targeting EGFR with antitumor activity that accelerates the internalization and degradation of EGFR.</p>Pureza:95.5% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.5% (SDS-PAGE); 99.3% (SEC-HPLC)Forma y color:LiquidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Forma y color:Odour SolidMatuzumab
CAS:<p>Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.</p>Pureza:95%Forma y color:LiquidPeso molecular:145.9 kDaEGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731Necitumumab
CAS:<p>Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.</p>Pureza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Forma y color:LiquidPeso molecular:145.5 kDaCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Forma y color:LiquidPeso molecular:150 kDaEGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H36N7O4PForma y color:SolidPeso molecular:589.625HER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H27ClFN7O2Peso molecular:571.18988PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Fórmula:C49H64ClFN10O7SForma y color:SolidPeso molecular:991.61BLU-945
CAS:<p>BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.</p>Fórmula:C28H37FN6O3SPureza:99.11% - 99.16%Forma y color:SolidPeso molecular:556.7SJF 1528
CAS:<p>Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).</p>Fórmula:C55H57ClFN7O8SForma y color:SolidPeso molecular:1030.61EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Forma y color:Odour SolidTephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Fórmula:C22H19ClN6O2SPureza:99.7%Forma y color:SolidPeso molecular:466.94EGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Fórmula:C26H22N6O2SPeso molecular:482.1525PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Fórmula:C27H22F6N2O2Peso molecular:520.15855EGFR kinase inhibitor 2
<p>EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.</p>Fórmula:C39H40N6O5Peso molecular:672.30602HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Forma y color:SolidPeso molecular:884.11EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Fórmula:C22H16ClFN4O2Peso molecular:422.09458AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21EGFR WT/T790M/L858R-IN-1
<p>EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.</p>Fórmula:C26H25Cl3N2O3Peso molecular:518.09308MS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Fórmula:C55H71ClFN9O7SPeso molecular:1056.73BMS-599626
CAS:<p>BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.</p>Fórmula:C27H27FN8O3Pureza:98.73%Forma y color:SolidPeso molecular:530.55Pertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Pureza:98.00%Forma y color:LiquidPeso molecular:148 kDaSJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Fórmula:C57H61ClFN7O9SPureza:99.20%Forma y color:SolidPeso molecular:1074.65JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SForma y color:SolidPeso molecular:670.67EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Forma y color:SolidPeso molecular:561.05Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Forma y color:LiquidEGFR-IN-129
<p>EGFR-IN-129 (Compound 10b) is an effective, selective EGFR inhibitor with an IC50 of 51.2 nM and demonstrates broad-spectrum antiproliferative activity against the NCI tumor panel.</p>Fórmula:C21H18N4O3SForma y color:SolidPeso molecular:406.46EP26
<p>EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.</p>Fórmula:C42H42ClFN4O5Peso molecular:736.28278EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Fórmula:C28H29N3O6Peso molecular:503.20564CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Fórmula:C42H53Cl2N5O3Forma y color:SolidPeso molecular:746.808EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Fórmula:C27H27N7O2Forma y color:SolidPeso molecular:481.55Pimurutamab
CAS:<p>Pimurutamab, a humanized IgG1-κ antibody, selectively targets the epidermal growth factor receptor (EGFR) and is primarily produced by CHO-K1 cells [1].</p>Pureza:98%Forma y color:LiquidCanertinib
CAS:Fórmula:C24H25ClFN5O3Pureza:>98.0%(HPLC)(qNMR)Forma y color:White to Light yellow powder to crystalPeso molecular:485.94Vandetanib
CAS:Fórmula:C22H24BrFN4O2Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:475.36Tyrphostin AG 879
CAS:Fórmula:C18H24N2OSPureza:>98.0%(HPLC)Forma y color:Light yellow to Yellow to Orange powder to crystalPeso molecular:316.46AV-412 free base
CAS:<p>AV-412 free base is an EGFR inhibitor (IC50s: 0.75, 0.79, 0.5, 2.3, 19 nM for EGFR, EGFR(T790M), EGFR(L858R), EGFR(L858R/T790M) and ErbB2).</p>Fórmula:C27H28ClFN6OForma y color:SolidPeso molecular:507Tyrphostin RG 14620
CAS:Fórmula:C14H8Cl2N2Pureza:>98.0%(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:275.13Erlotinib-d6
CAS:<p>Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib .</p>Fórmula:C22H23N3O4Pureza:98%Forma y color:SolidPeso molecular:399.47Osimertinib dimesylate
CAS:<p>Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).</p>Fórmula:C30H41N7O8S2Pureza:98%Forma y color:SolidPeso molecular:691.82CL-387785
CAS:Fórmula:C18H13BrN4OPureza:>98.0%(GC)Forma y color:White to Light yellow powder to crystalPeso molecular:381.23Mavelertinib
CAS:<p>Mavelertinib (PF-06747775) is an EGFR tyrosine kinase (EGFR TKI) inhibitor that inhibits T790M/L858R and can be used to study tumours.</p>Fórmula:C18H22FN9O2Pureza:99.89%Forma y color:SolidPeso molecular:415.42
![Propanedinitrile,2-[(4-methoxyphenyl)methylene]-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA007L0Q.webp&w=3840&q=75)
![1-[4-[4-[[2-[(1E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA0078T8.webp&w=3840&q=75)
![(2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimeth…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA0035DM.webp&w=3840&q=75)
![N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA0039KT.webp&w=3840&q=75)
![2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA00ABJJ.webp&w=3840&q=75)
![N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA0039KY.webp&w=3840&q=75)
![(2E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-[(1S)-1-phenylethyl]-2-propenamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA003988.webp&w=3840&q=75)
